Cardiome Pharma Corp. (CRME) Forms $1.57 Double Bottom; Johnson Matthey Plc (LON:JMAT) Covered By 10 Bullish Analysts Last Week

Among 16 analysts covering Johnson Matthey PLC (LON:JMAT), 10 have Buy rating, 1 Sell and 5 Hold. Therefore 63% are positive. Johnson Matthey PLC had 161 analyst reports since July 23, 2015 according to SRatingsIntel. The stock of Johnson Matthey Plc (LON:JMAT) earned “Neutral” rating by BNP Paribas on Thursday, September 3. UBS maintained the stock with “Neutral” rating in Friday, January 29 report. The firm has “Outperform” rating given on Friday, February 3 by Credit Suisse. The firm has “Buy” rating given on Friday, November 18 by Deutsche Bank. The stock of Johnson Matthey Plc (LON:JMAT) has “Hold” rating given on Thursday, November 19 by Liberum Capital. The stock has “Buy” rating by Citigroup on Wednesday, November 22. As per Thursday, February 4, the company rating was maintained by JP Morgan. The firm has “Buy” rating given on Friday, June 16 by Deutsche Bank. The company was maintained on Tuesday, July 21 by Numis Securities. The firm earned “Buy” rating on Wednesday, April 6 by Deutsche Bank. See Johnson Matthey Plc (LON:JMAT) latest ratings:

13/12/2017 Broker: Barclays Capital Rating: Overweight Maintain
12/12/2017 Broker: Citigroup Rating: Buy Old Target: GBX 4000.00 New Target: GBX 4000.00 Maintain
22/11/2017 Broker: Citigroup Rating: Buy New Target: GBX 4000.00 Maintain
22/11/2017 Broker: JP Morgan Rating: Neutral Old Target: GBX 3400.00 New Target: GBX 3400.00 Maintain
21/11/2017 Broker: Liberum Capital Rating: Hold Old Target: GBX 3400.00 New Target: GBX 3400.00 Maintain
16/11/2017 Broker: Barclays Capital Rating: Overweight Maintain
13/11/2017 Broker: Morgan Stanley Rating: Overweight Old Target: GBX 3500.00 New Target: GBX 3900.00 Reiteration
10/10/2017 Broker: JP Morgan Rating: Neutral Old Target: GBX 3200.00 New Target: GBX 3400.00 Maintain
29/09/2017 Broker: Deutsche Bank Rating: Buy Old Target: GBX 3600.00 New Target: GBX 4300.00 Maintain
22/09/2017 Broker: Morgan Stanley Rating: Overweight Old Target: GBX 3500.00 New Target: GBX 3500.00 Maintain

Cardiome Pharma Corp. (CRME) formed double bottom with $1.48 target or 6.00% below today’s $1.57 share price. Cardiome Pharma Corp. (CRME) has $55.97M valuation. The stock decreased 2.79% or $0.0452 during the last trading session, reaching $1.5748. About 107,251 shares traded. Cardiome Pharma Corp. (NASDAQ:CRME) has declined 11.02% since December 29, 2016 and is downtrending. It has underperformed by 27.72% the S&P500.

The stock decreased 0.39% or GBX 12 during the last trading session, reaching GBX 3079. About 55,139 shares traded. Johnson Matthey Plc (LON:JMAT) has 0.00% since December 29, 2016 and is . It has underperformed by 16.70% the S&P500.

Johnson Matthey Plc operates as a specialty chemicals firm in North America, Europe, China, rest of Asia, and internationally. The company has market cap of 5.91 billion GBP. It operates in five divisions: Emission Control Technologies, Process Technologies, Precious Metal Products, Fine Chemicals, and New Businesses. It has a 15.71 P/E ratio. The Emission Control Technologies division makes catalysts, which control harmful emissions from cars and other light duty vehicles powered by various types of fuel, as well as from diesel powered trucks, buses, and non-road machinery.

Analysts await Cardiome Pharma Corp. (NASDAQ:CRME) to report earnings on March, 6. They expect $-0.19 EPS, down 5.56% or $0.01 from last year’s $-0.18 per share. After $-0.20 actual EPS reported by Cardiome Pharma Corp. for the previous quarter, Wall Street now forecasts -5.00% EPS growth.

Among 6 analysts covering Cardiome Pharma Corp (NASDAQ:CRME), 6 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Cardiome Pharma Corp had 15 analyst reports since August 11, 2015 according to SRatingsIntel. The stock of Cardiome Pharma Corp. (NASDAQ:CRME) has “Buy” rating given on Tuesday, August 22 by H.C. Wainwright. The stock of Cardiome Pharma Corp. (NASDAQ:CRME) earned “Buy” rating by Zacks on Tuesday, August 11. Mackie upgraded the stock to “Buy” rating in Friday, December 15 report. On Monday, July 17 the stock rating was reinitiated by Canaccord Genuity with “Buy”. The stock of Cardiome Pharma Corp. (NASDAQ:CRME) has “Outperform” rating given on Thursday, December 22 by Leerink Swann. The firm earned “Buy” rating on Wednesday, November 15 by Canaccord Genuity. The stock of Cardiome Pharma Corp. (NASDAQ:CRME) has “Buy” rating given on Wednesday, June 1 by H.C. Wainwright. The company was maintained on Friday, March 11 by Brean Capital. LB Securities reinitiated the stock with “Buy” rating in Friday, August 14 report. The rating was downgraded by Mackie to “Hold” on Wednesday, October 12.

Investors sentiment increased to 1.09 in 2017 Q3. Its up 0.26, from 0.83 in 2017Q2. It improved, as 2 investors sold Cardiome Pharma Corp. shares while 9 reduced holdings. 7 funds opened positions while 5 raised stakes. 13.54 million shares or 10.92% less from 15.20 million shares in 2017Q2 were reported. Knott David M stated it has 134,478 shares or 0.12% of all its holdings. Massachusetts-based Westfield Capital Management Lp has invested 0.08% in Cardiome Pharma Corp. (NASDAQ:CRME). Royal Savings Bank Of Canada accumulated 0% or 1,889 shares. Putnam Lc stated it has 0.02% of its portfolio in Cardiome Pharma Corp. (NASDAQ:CRME). Renaissance Technologies Ltd Limited Liability Company holds 0% or 411,413 shares in its portfolio. 10,000 were reported by Jefferies Group Lc. Morgan Stanley has invested 0% of its portfolio in Cardiome Pharma Corp. (NASDAQ:CRME). Ontario – Canada-based Bank & Trust Of Nova Scotia Trust Communication has invested 0% in Cardiome Pharma Corp. (NASDAQ:CRME). National Bank Of America De has 45 shares. Wells Fargo & Mn reported 0% in Cardiome Pharma Corp. (NASDAQ:CRME). Pnc Fincl Services has invested 0% of its portfolio in Cardiome Pharma Corp. (NASDAQ:CRME). Jpmorgan Chase And accumulated 158,697 shares or 0% of the stock. Toronto Dominion Natl Bank has 84 shares. Virtu Fincl Limited Liability Corporation holds 0% in Cardiome Pharma Corp. (NASDAQ:CRME) or 27,658 shares. Art Advsr Limited Com, a New York-based fund reported 16,718 shares.